• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

NY Rep. Collins loses millions on Innate flop

June 28, 2017 By Sarah Faulkner

Innate ImmunotherapeuticsEarlier this year, Rep. Chris Collins’ (R-NY) 16.8% stake in Innate Immunotherapeutics (ASX:IIL) was worth $45.5 million. But since the Australian biotech’s lead drug failed in a 93-patient trial this week, shares in the company dropped to 4¢ apiece and Collins’ holdings are now valued at just $1.5 million.

As the company’s largest investor and a board member, Collins has previously encouraged his congressional colleagues to back the company. Elected officials who have purchased stock based on Collins’ recommendation includes now Health and Human Services Secretary Tom Price, who bought Innate shares in 2015 and 2016 while he was a member of the House.

Michael Hook, Collin’s chief of staff is one of Innate’s top 20 shareholders. Two of his children are also on that list.

Price reportedly liquidated his stake in Innate in February, according to Stat. 

“For those that invested in Innate, including me, we all were sophisticated investors who were aware of the inherent risk,” Collins said in a statement this week. “For every successful drug, there are countless numbers that fail. That’s how today’s system works.”

“These results are a shock and definitely not what we were expecting based on our previous clinical experience with MIS416 and the reporting of treatment benefits we have received from many compassionate use patients over an extensive 8-year period. These data will be as distressing to them as they will be for all the stakeholders who were relying on the outcome of this study,” CEO Simon Wilkinson said in prepared remarks.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Featured, Immunotherapy, Pharmaceuticals, Policy, Wall Street Beat Tagged With: innateimmunotherapeutics

IN CASE YOU MISSED IT

  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China
  • Convatec wins FDA approval for Parkinson’s treatment infusion tech

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS